semaglutide cv benefit Cardiovascular risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline risk profile in the SUSTAIN 6 trial Effects of semaglutide on risk
Description
Tirzepatide, developed by Eli Lilly, has already achieved FDA approval and commercial success as Mounjaro (type 2 diabetes) and Zepbound (obesity)
Pricing remains flat at $149/month regardless of dose adjustments
According to Professor Jeon, semaglutide has been shown to have a weight loss rate of 5 percent in 86 percent of patients and a weight loss rate of 20 percent or more in nearly 30 percent
Please call, text, or email us if you have any questions
